Agreed, if demand is high for their product big pharma will pay top price for licensing rights. Regardless, at this point in the game, it's all going to come down to product demand. I think big pharmas are in a wait and see mode allowing AVNR to "show their stuff" thus minimizing their risk. JMHO GLTA
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.